Prevention of venous thromboembolism in hip surgery

  • D. Janssen


Until heparins were introduced to clinical practice at the start of the 1970s, thromboembolic events were common complications which jeopardized the outcome of surgery. Without prophylaxis, risk of deep vein thrombosis (DVT) was 40–60% in hospitalized patients undergoing major orthopaedic surgery (Geerts et al. 2004). Therefore patients with hip surgery should be assigned to the
  • ‘high-risk group’ for thromboses as classified in the German Guidelines (Encke et al. 2003) or

  • ‘highest risk group’ as defined by the “Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy” (Geerts et al. 2004). The rates of venous thromboembolism (VTE) found in patients receiving either placebo or no prophylaxis are listed in Table 18.1.


Venous Thromboembolism Unfractionated Heparin Major Orthopaedic Surgery Chronic Venous Insufficiency Multidose Vial 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Arnesen H, Dahl OE, Aspelin T, Seljeflot I, Kierulf P, Lyberg T (2003) Sustained prothrombotic profile after hip replacement surgery: the influence of prolonged prophylaxis with dalteparin. J Thromb Haemost 1:971–975PubMedCrossRefGoogle Scholar
  2. 2.
    Bergqvist D, Burmark US, Flordal PA, Frisell J, Hallbook T, Hedberg M, Horn A, Kelty E, Kvitting P, Lindhagen A et al (1995) Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 Xa units in 2070 patients. Br J Surg 82:496–501PubMedCrossRefGoogle Scholar
  3. 3.
    Bergqvist D, Benoni G, Bjorgell O, Fredin H, Hedlundh U, Nicolas S, Nilsson P, Nylander G (1996) Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med 335:696–700PubMedCrossRefGoogle Scholar
  4. 4.
    Bergqvist D, Hull RD (2006) Effective thromboprophylaxis administered close to the time of major orthopedic surgery: a review. Am J Orthop 226–230Google Scholar
  5. 5.
    Comp PC, Spiro TE, Friedman RJ, Whitsett TL, Johnson GJ, Gardiner GA, Landon GC, Jove M (2001) Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Enoxaparin Clinical Trial Group. J Bone Joint Surg Am 83:336–345Google Scholar
  6. 6.
    Dahl OE, Andreassen G, Aspelin T, Muller C, Mathiesen P, Nyhus S, Abdelnoor M, Solhaug JH, Arnesen H (1997) Prolonged thromboprophylaxis following hip replacement surgery — results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin). Thromb Haemost 77:26–31PubMedGoogle Scholar
  7. 7.
    Encke A, Haas S, Krauspe R, Riess H, Stürmer KM (2003) Stationäre und ambulante Thromboembolie-Prophylaxe in der Chirurgie und der Perioperativen Medizin. Beilage zu den Mitteilungen der Deutschen Gesellschaft für Chirurgie, G97Google Scholar
  8. 8.
    Eriksson BI, Kalebo P, Anthymyr BA, Wadenvik H, Tengborn L, Risberg B (1991) Prevention of deep-vein thrombosis and pulmonary embolism after total hip replacement. Comparison of low-molecular-weight heparin and unfractionated heparin. J Bone Joint Surg Am 73: 484–493PubMedGoogle Scholar
  9. 9.
    Eriksson BI, Lassen MR, the PENTasaccharid in HIp-FRActure Surgery Plus (PENTHIFRA Plus) Investigators (2003) Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study. Arch Intern Med 163:1337–1342PubMedCrossRefGoogle Scholar
  10. 10.
    Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG (2004) Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (3 Suppl):338S–400SPubMedCrossRefGoogle Scholar
  11. 11.
    Greinacher A (2007) Lepirudin in clinical practice. Refludan® (lepirudin) in acute HIT, 1st ed. Socio-medico, Wessobrunn, ISSN 1864-7219Google Scholar
  12. 12.
    Hass S (1998) Medizinische Grundlagen und medico-legale Aspekte der venösen Thromboembolieprophylaxe. Chirurg BDC 37:242–250Google Scholar
  13. 13.
    Hull RD, Pineo GF, Francis C, Bergqvist D, Fellenius C, Soderberg K, Holmqvist A, Mant M, Dear R, Baylis B, Mah A, Brant R (2000) Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. North American Fragmin Trial Investigators. Arch Intern Med 160:2208–2215Google Scholar
  14. 14.
    Hull RD, Pineo GF, Francis C, Bergqvist D, Fellenius C, Soderberg K, Holmqvist A, Mant M, Dear R, Baylis B, Mah A, Brant R (2000) Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: a double-blind, randomized comparison. The North American Fragmin Trial Investigators. Arch Intern Med 160:2199–2207Google Scholar
  15. 15.
    Lassen MR, Borris LC, Anderson BS, Jensen HP, Skejo Bro HP, Andersen G, Petersen AO, Siem P, Horlyck E, Jensen BV, Thomsen PB, Hansen BR, Erin-Madsen J, Moller JC, Rotwitt L, Christensen F, Nielsen JB, Jorgensen PS, Paaske B, Torholm C, Hvidt P, Jensen NK, Nielsen AB, Appelquist E, Tjalve E et al (1998) Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty — the Danish Prolonged Prophylaxis (DaPP) Study. Thromb Res 89:281–287PubMedCrossRefGoogle Scholar
  16. 16.
    Mahe I, Aghassarian M, Drouet L, Dit-Sollier CB, Lacut K, Heilmann JJ, Mottier D, Bergmann JF (2007) Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function: a comparative pharmacokinetic study. Thromb Haemost 97:581–586PubMedGoogle Scholar
  17. 17.
    Pauschert R, Diehm C, Stammler F (1998) Guidelines for prevention of thrombosis in orthopedics [Leitlinien zur Thromboseprophylaxe in der Orthopädie]. Z Orthop Ihre Grenzgeb 136:471–479PubMedCrossRefGoogle Scholar
  18. 18.
    Pettila V, Leinonen P, Markkola A, Hiilesmaa V, Kaaja R (2002) Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thromb Haemost 87:182–186PubMedGoogle Scholar
  19. 19.
    Planes A, Vochelle N, Darmon JY, Fagola M, Bellaud M, Huet Y (1996) Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo. Lancet 348:224–228PubMedCrossRefGoogle Scholar
  20. 20.
    Rapp M, Felenda M-R, Dittel K-K (2001) Thromboprophylaxis by low-molecular-weight heparin (Fragmin) in surgery at the proximal femur — a comparative study of multidose vials versus syringes (Abstract). 8th International Symposium on Thromboembolism, Florenz/Italien, Abstrakt Band, S 37Google Scholar
  21. 21.
    Rodger MA, Kahn SR, Cranney A, Hodsman A, Kovacs MJ, Clement AM, Lazo-Langner A, Hague WM (2007) Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial. J Thromb Haemost 5:1600–1606PubMedCrossRefGoogle Scholar
  22. 22.
    Stöbe J, Siegemund A, Achenbach H, Preiss C, Preiss R (2006) Evaluation of the pharmacokinetics of dalteparin in patients with renal insufficiency. Int J Clin Pharmacol Ther 44:455–465PubMedGoogle Scholar
  23. 23.
    Tincani E, Mannucci C, Casolari B, Turrini F, Crowther MA, Prisco D, Cenci AM, Bondi M (2006) Safety of dalteparin for the prophylaxis of venous thromboembolism in elderly medical patients with renal insufficiency: a pilot study. Haematologica 91:976–979PubMedGoogle Scholar
  24. 24.
    Warkentin TE, Greinacher A (2007) Heparin-induced thrombocytopenia, 4th ed. revised and expanded. Marcel Dekker, New York BaselGoogle Scholar
  25. 25.
    White RH, Gettner S, Newman JM, Trauner KB, Romano PS (2000) Predictors of rehospitalization for symptomatic venous thromboembolism after total hip arthroplasty. N Engl J Med 343:1758–1764PubMedCrossRefGoogle Scholar

Copyright information

© Steinkopff Verlag 2008

Authors and Affiliations

  • D. Janssen
    • 1
  1. 1.Med-i-Scene Concept GmbHWeisendorf

Personalised recommendations